XTL Biopharmaceuticals Ltd. (XTLB)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20269 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to XTL Biopharmaceuticals Ltd.’s names, not what it holds today.
4 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Dec 11, 2012 | 8,329,703 | Pyrazole compounds | Organic fine chemistry | XTL BIOPHARMACEUTICALS LTD. |
| Mar 27, 2012 | 8,143,276 | 4-thio substituted quinoline and naphthyridine compounds | Organic fine chemistry | XTL BIOPHARMACEUTICALS LTD. |
| Nov 1, 2011 | 8,048,889 | 3,4-disubstituted coumarin and quinolone compounds | Pharmaceuticals | XTL BIOPHARMACEUTICALS LTD. |
| Aug 9, 2011 | 7,994,360 | Benzofuran compounds | Organic fine chemistry | XTL BIOPHARMACEUTICALS LTD. |
| Apr 12, 2011 | 7,923,004 | 4-ethynyl pyrazole derivative compounds and methods for treatment of HCV | Organic fine chemistry | XTL BIOPHARMACEUTICALS LTD. |
| Apr 24, 2007 | RE39,586 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVSAG) | XTL BIOPHARMACEUTICALS LTD. | |
| Dec 12, 2006 | 7,148,253 | 4-thio coumarins | Organic fine chemistry | XTL BIOPHARMACEUTICALS LTD. |
| Jul 3, 2001 | 6,254,867 | Human monoclonal antibodies to the hepatitis B surface antigen | Medical technology | XTL BIOPHARMACEUTICALS LTD. |
| Nov 14, 2000 | 6,146,629 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg) | Pharmaceuticals | XTL BIOPHARMACEUTICALS LTD. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Oct 29, 2020 | 2020/0338195 | PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | Pharmaceuticals | XTL BIOPHARMACEUTICALS LTD. |
| Feb 15, 2018 | 2018/0043017 | PHARMACEUTICAL COMPOSITIONS COMPRISING 0.5 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | Pharmaceuticals | XTL BIOPHARMACEUTICALS LTD. |
| Feb 15, 2018 | 2018/0043016 | PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | Pharmaceuticals | XTL BIOPHARMACEUTICALS LTD. |
| Nov 24, 2005 | 2005/0260195 | Treatment of hepatitis B virus infection with human monoclonal antibodies | Pharmaceuticals | XTL BIOPHARMACEUTICALS LTD. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.